drugset
drugset / Trial / NCT05334108

Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport

NCT05334108 ↗

Phase 1 Completed 56 enrolled Emalex Biosciences Inc. ICON plc · collabNuventra, Inc. · collab
Non-randomizedParallel-groupOpen-labelBasic science

Summary

This is a single center, open-label, fixed sequence Phase 1, drug-drug interaction (DDI) study in healthy subjects.

Timeline

Start
2022-04-26
Primary completion
2022-08-01
Completion
2022-08-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule 100 ug Oral
Subject Bupropion Small molecule 100 mg —
Subject Caffeine Small molecule 200 mg Oral
Subject Dabigatran Unknown 375 ug Oral
Subject Dextromethorphan Unknown 10 mg Oral
Subject Ecopipam Small molecule 2 mg/kg Oral
Subject Midazolam Small molecule 1 ug Intravenous
Subject Midazolam Small molecule 10 ug Intravenous
Subject Omeprazole Other / unclassified 40 mg Oral
Subject Pitavastatin Small molecule 10 ug Oral
Subject Rosuvastatin Small molecule 50 ug Oral

Indications

No indication recorded.